ANVISA’s home brewed scaling? [RSABE / ABEL]

posted by Lucas – Brazil, 2015-06-02 18:02 (4044 d 15:38 ago) – Posting: # 14897
Views: 11,850

Hello guys.

Very interesting indeed, huh? We've also received that kind of feedback, it's a standard response when ANVISA is questioned about BE approaches for HVDs. From what I heard here, the first approach described by HS up here is the one that they want. Same regulatory constant.
They think that drugs with variability between 30% and 40% are not HVDs in fact, since the rate of BE approval in this range is acceptable, according to them. IMHO that affirmation is reasonable, but how would that be used together with EMA's ABEL I wouldn't know how.

For sure planning a study in those conditions is very hard. Very few people have tried scaling for ANVISA, since it's not yet very well established how it should be done.

Hope to have been of help. Best regards.

Lucas

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
394 visitors (0 registered, 394 guests [including 17 identified bots]).
Forum time: 09:40 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5